Filter

Refine by date

—

Refine by collections

  • Print
  • Save

Search Results

You are looking at 1 - 5 of 5 items for :

  • "Alemtuzumab" x
Clear All
Ilaria Muller Department of Clinical Sciences and Community Health, University of Milan, Italy
Endocrinology Unit, Graves’ Orbitopathy Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

Search for other papers by Ilaria Muller in
Google Scholar
PubMed Close
,
Sara Maioli Department of Clinical Sciences and Community Health, University of Milan, Italy

Search for other papers by Sara Maioli in
Google Scholar
PubMed Close
,
Mirco Armenti Department of Clinical Sciences and Community Health, University of Milan, Italy

Search for other papers by Mirco Armenti in
Google Scholar
PubMed Close
,
Laura Porcaro Department of Clinical Sciences and Community Health, University of Milan, Italy

Search for other papers by Laura Porcaro in
Google Scholar
PubMed Close
,
Nicola Currò Endocrinology Unit, Graves’ Orbitopathy Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
Ophthalmology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

Search for other papers by Nicola Currò in
Google Scholar
PubMed Close
,
Elisabetta Iofrida Department of Specialistic Surgical Sciences, Otolaryngology and Head and Neck Surgery, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

Search for other papers by Elisabetta Iofrida in
Google Scholar
PubMed Close
,
Lorenzo Pignataro Department of Clinical Sciences and Community Health, University of Milan, Italy
Department of Specialistic Surgical Sciences, Otolaryngology and Head and Neck Surgery, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

Search for other papers by Lorenzo Pignataro in
Google Scholar
PubMed Close
,
Jacopo Manso Endocrinology Unit, Department of Medicine (DIMED), University of Padova, Padova, Italy

Search for other papers by Jacopo Manso in
Google Scholar
PubMed Close
,
Caterina Mian Endocrinology Unit, Department of Medicine (DIMED), University of Padova, Padova, Italy

Search for other papers by Caterina Mian in
Google Scholar
PubMed Close
,
Jens Geginat Department of Clinical Sciences and Community Health, University of Milan, Italy
National Institute of Molecular Genetics (INGM) “Romeo and Enrica Invernizzi”, Milan, Italy

Search for other papers by Jens Geginat in
Google Scholar
PubMed Close
, and
Mario Salvi Endocrinology Unit, Graves’ Orbitopathy Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

Search for other papers by Mario Salvi in
Google Scholar
PubMed Close

Ours is the first description of the immune cell profiling derived from the consecutive administration of alemtuzumab for multiple sclerosis and rituximab for thyroid eye disease. B-cell depletion induced by rituximab is an effective treatment for

Article Type:
Case Report
Collections:
Thyroid autoimmunity
DOI:
https://doi.org/10.1530/ETJ-23-0236
Volume/Issue:
Volume 13: Issue 2
Open access
Ilaria Muller Thyroid Research Group, Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom

Search for other papers by Ilaria Muller in
Google Scholar
PubMed Close
,
Carla Moran Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom

Search for other papers by Carla Moran in
Google Scholar
PubMed Close
,
Beatriz Lecumberri Department of Endocrinology and Nutrition, La Paz University Hospital, IdiPAZ, Autonomous University of Madrid, Madrid, Spain

Search for other papers by Beatriz Lecumberri in
Google Scholar
PubMed Close
,
Brigitte Decallonne Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium

Search for other papers by Brigitte Decallonne in
Google Scholar
PubMed Close
,
Neil Robertson Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, United Kingdom

Search for other papers by Neil Robertson in
Google Scholar
PubMed Close
,
Joanne Jones Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom

Search for other papers by Joanne Jones in
Google Scholar
PubMed Close
, and
Colin M. Dayan Thyroid Research Group, Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom

Search for other papers by Colin M. Dayan in
Google Scholar
PubMed Close

recovery of immune cell numbers following a depletion phase, which to date has been reported in 3 settings: (1) following alemtuzumab (Lemtrada) treatment for active relapsing remitting multiple sclerosis (MS); (2) after treatment of human immunodeficiency

Article Type:
Review Article
DOI:
https://doi.org/10.1159/000500881
Volume/Issue:
Volume 8: Issue 4
Open access
Earn H. Gan Institute of Genetic Medicine, International Centre for Life, Newcastle upon Tyne, United Kingdom

Search for other papers by Earn H. Gan in
Google Scholar
PubMed Close
,
Anna L. Mitchell Institute of Genetic Medicine, International Centre for Life, Newcastle upon Tyne, United Kingdom

Search for other papers by Anna L. Mitchell in
Google Scholar
PubMed Close
,
Ruth Plummer Institute of Genetic Medicine, International Centre for Life, Newcastle upon Tyne, United Kingdom

Search for other papers by Ruth Plummer in
Google Scholar
PubMed Close
,
Simon Pearce Institute of Genetic Medicine, International Centre for Life, Newcastle upon Tyne, United Kingdom

Search for other papers by Simon Pearce in
Google Scholar
PubMed Close
, and
Petros Perros Institute of Genetic Medicine, International Centre for Life, Newcastle upon Tyne, United Kingdom

Search for other papers by Petros Perros in
Google Scholar
PubMed Close

immunotherapy, such as alemtuzumab, a human anti-CD52 monoclonal antibody therapy, with onset ranging from 6 to 61 months after the first course of treatment [ 29 , 30 ]. One might suggest that our case was an incidental finding of isolated Graves disease

Article Type:
Case Report
DOI:
https://doi.org/10.1159/000464285
Volume/Issue:
Volume 6: Issue 3
Free access
Alessandro Brancatella Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy

Search for other papers by Alessandro Brancatella in
Google Scholar
PubMed Close
,
Nicola Viola Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy

Search for other papers by Nicola Viola in
Google Scholar
PubMed Close
,
Sandra Brogioni Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy

Search for other papers by Sandra Brogioni in
Google Scholar
PubMed Close
,
Lucia Montanelli Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy

Search for other papers by Lucia Montanelli in
Google Scholar
PubMed Close
,
Chiara Sardella Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy

Search for other papers by Chiara Sardella in
Google Scholar
PubMed Close
,
Paolo Vitti Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy

Search for other papers by Paolo Vitti in
Google Scholar
PubMed Close
,
Claudio Marcocci Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy

Search for other papers by Claudio Marcocci in
Google Scholar
PubMed Close
,
Isabella Lupi Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy

Search for other papers by Isabella Lupi in
Google Scholar
PubMed Close
, and
Francesco Latrofa Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy

Search for other papers by Francesco Latrofa in
Google Scholar
PubMed Close

autoimmune hyperthyroidism and Graves’ ophthalmopathy. Of note, euthyroid Graves’ ophthalmopathy is very uncommon after other immunotherapy drugs (e.g., interferon and alemtuzumab); in these settings, ophthalmopathy is usually associated with hyperthyroidism

Article Type:
Case Report
DOI:
https://doi.org/10.1159/000501824
Volume/Issue:
Volume 8: Issue 4
Free access
George J. Kahaly Department of Medicine I, Johannes Gutenberg University (JGU) Medical Center, Mainz, Germany

Search for other papers by George J. Kahaly in
Google Scholar
PubMed Close
,
Luigi Bartalena Department of Medicine and Surgery, University of Insubria, Varese, Italy

Search for other papers by Luigi Bartalena in
Google Scholar
PubMed Close
,
Lazlo Hegedüs Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark

Search for other papers by Lazlo Hegedüs in
Google Scholar
PubMed Close
,
Laurence Leenhardt Thyroid and Endocrine Tumors Unit, Pitié Salpêtrière Hospital, Sorbonne University, Paris, France

Search for other papers by Laurence Leenhardt in
Google Scholar
PubMed Close
,
Kris Poppe Endocrine Unit, CHU Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium

Search for other papers by Kris Poppe in
Google Scholar
PubMed Close
, and
Simon H. Pearce Department of Endocrinology, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom

Search for other papers by Simon H. Pearce in
Google Scholar
PubMed Close

-depleting alemtuzumab (Campath-H1) antibody treatment [ 161 ]. This treatment causes initial lymphopenia, but 12–24 months later 20–30% of patients developed TSH-R-Ab-positive GD, as lymphocyte populations recover. A similar pattern of GD has been observed in patients

Article Type:
Guideline
DOI:
https://doi.org/10.1159/000490384
Volume/Issue:
Volume 7: Issue 4
Free access